MCID: OVR094
MIFTS: 46

Ovarian Epithelial Cancer

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 49 28
Epithelial Ovarian Cancer 49 69
Ovarian Epithelial Carcinoma 49
Ovarian Cancer, Epithelial 49
Eoc 49

Classifications:



Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to ovarian cancer 1 and ovarian cancer. An important gene associated with Ovarian Epithelial Cancer is MUC4 (Mucin 4, Cell Surface Associated), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Focal Adhesion. The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and t cells, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Related Diseases for Ovarian Epithelial Cancer

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

MGI Mouse Phenotypes related to Ovarian Epithelial Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.98 PHB AKT2 PTGS1 BIRC5 COL1A1 PTGS2
2 homeostasis/metabolism MP:0005376 9.95 MAPK1 PHB AKT2 BIRC5 PTGS1 COL1A1
3 mortality/aging MP:0010768 9.87 MAPK1 PHB AKT2 BIRC5 PTGS1 COL1A1
4 integument MP:0010771 9.85 PHB AKT2 PTGS1 COL1A1 PTGS2 MAPK1
5 muscle MP:0005369 9.65 MAPK1 AKT2 PTGS1 COL1A1 PTGS2
6 neoplasm MP:0002006 9.55 AKT2 PTGS1 COL1A1 PTGS2 MAPK1
7 reproductive system MP:0005389 9.43 PHB AKT2 PTGS1 COL1A1 PTGS2 MAPK1
8 respiratory system MP:0005388 9.02 AKT2 PTGS1 COL1A1 PTGS2 MAPK1

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 460)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
5
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 763113-22-0 23725625
6
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
7 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
8 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
10 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
13 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
18
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 119413-54-6, 123948-87-8 60700
19
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
20
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
21
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
22
Ifosfamide Approved Phase 2, Phase 3, Phase 1 3778-73-2 3690
23
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
24
Mechlorethamine Approved, Investigational Phase 2, Phase 3, Phase 1 51-75-2 4033
25
Oxaliplatin Approved, Investigational Phase 3,Phase 1,Phase 2 61825-94-3 43805 6857599 5310940 9887054
26
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2 135968-09-1
27
Pancrelipase Approved, Investigational Phase 3,Phase 1,Phase 2 53608-75-6
28
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
29
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
30
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757
31
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 460612 4053
32
Morphine Approved, Investigational Phase 3 57-27-2 5288826
33
Captopril Approved Phase 3 62571-86-2 44093
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
35
Ribavirin Approved Phase 3 36791-04-5 37542
36
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
37
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
38
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
39
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
40
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
41
Itraconazole Approved, Investigational Phase 3,Phase 1,Phase 2 84625-61-6 55283
42
Pertuzumab Approved Phase 3,Phase 2 380610-27-5, 145040-37-5 2540
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
44
Palivizumab Approved, Investigational Phase 3 188039-54-5
45
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
46
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
47
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
48
Acetylcarnitine Approved, Investigational Phase 3,Phase 2 3040-38-8 1
49
Rucaparib Approved, Investigational Phase 3,Phase 2 283173-50-2 9931954
50
Letrozole Approved, Investigational Phase 2, Phase 3,Early Phase 1 112809-51-5 3902

Interventional clinical trials:

(show top 50) (show all 996)

# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
2 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
3 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
4 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
5 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
6 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
7 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
8 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
9 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
10 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
11 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
12 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
13 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
14 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
15 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
16 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
17 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
18 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
19 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
20 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
21 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
22 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
23 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
24 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
25 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Completed NCT00004166 Phase 3 amifostine trihydrate
26 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
27 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) Completed NCT01684878 Phase 3 Gemcitabine (Chemotherapy);Paclitaxel (Chemotherapy);Pertuzumab;Placebo;Topotecan (Chemotherapy)
28 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
30 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
31 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
32 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
33 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer Completed NCT00102414 Phase 3 Gemcitabine
34 Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
35 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3 carboplatin;cisplatin
36 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer Completed NCT00052468 Phase 3 TCG;TC
37 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
38 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
39 Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer Completed NCT00426257 Phase 3
40 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3 Topotecan
41 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
42 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
43 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
44 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
45 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
46 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
47 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
48 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
49 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
50 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

# Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 28

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

38
Breast, Bone, T Cells, Lung, Bone Marrow, Ovary, Liver

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 83)
# Title Authors Year
1
Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. ( 28693156 )
2017
2
Stably Fluorescent Cell Line of Human Ovarian Epithelial Cancer Cells SK-OV-3ip-red. ( 29124539 )
2017
3
Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation. ( 28685546 )
2017
4
Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. ( 27017986 )
2016
5
Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. ( 27445438 )
2016
6
Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. ( 26554540 )
2015
7
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. ( 26408685 )
2015
8
Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. ( 26137074 )
2015
9
Overexpression of Class III I^-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. ( 26198101 )
2015
10
Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway. ( 26261554 )
2015
11
Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. ( 25609006 )
2015
12
Prognostic Factors for Ovarian Epithelial Cancer in the Elderly: A Case-Control Study. ( 25768081 )
2015
13
Inhibitory role of prohibitin in human ovarian epithelial cancer. ( 24966933 )
2014
14
Ovarian sarcoma carries a poorer prognosis than ovarian epithelial cancer throughout all FIGO stages: a single-center case-control matched study. ( 25503164 )
2014
15
The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells. ( 23254909 )
2013
16
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. ( 23652306 )
2013
17
Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. ( 23708102 )
2013
18
Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. ( 24133590 )
2013
19
Over-expression of semaphorin4D, hypoxia-inducible factor-1I+ and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. ( 23202951 )
2012
20
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. ( 23189165 )
2012
21
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 22895947 )
2012
22
Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via I^1 integrin and PTEN signals. ( 23013730 )
2012
23
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. ( 22985132 )
2012
24
Ovarian epithelial cancer stem cells. ( 21666993 )
2011
25
Novel approaches to quantify estradiol-induced loss of ERI^1 protein in older mouse ovarian surface epithelium: new tools to assess the role of ER protein subtypes in predisposing to ovarian epithelial cancer? ( 21773845 )
2011
26
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer. ( 19945796 )
2010
27
Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. ( 21074685 )
2010
28
A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer. ( 20600897 )
2010
29
High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. ( 20811671 )
2010
30
[Effects of PTEN over-expression on phosphatidyl inositol 3-kinase/protein kinase B signal pathway in ovarian epithelial cancer cells]. ( 21092549 )
2010
31
Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. ( 19181441 )
2009
32
Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. ( 18676764 )
2008
33
[Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. ( 19173805 )
2008
34
Multitargeting ovarian epithelial cancer: adding the old to the new. ( 18349413 )
2008
35
Two-tier grading system for ovarian epithelial cancer: has its time arrived? ( 17667555 )
2007
36
Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. ( 17712227 )
2007
37
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 17943850 )
2007
38
[Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens]. ( 18476518 )
2007
39
Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. ( 17549341 )
2007
40
Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. ( 17906381 )
2007
41
[Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. ( 17673045 )
2007
42
Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. ( 16936295 )
2006
43
Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. ( 16961294 )
2006
44
Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons. ( 16707225 )
2006
45
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. ( 17107625 )
2006
46
Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. ( 15944801 )
2005
47
Aromatase expression in ovarian epithelial cancers. ( 15748828 )
2005
48
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. ( 15867369 )
2005
49
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. ( 15171311 )
2004
50
Borderline ovarian epithelial cancer. ( 21213507 )
2004

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
3 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

Pathways related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.76 AKT2 COL1A1 MAPK1 PTGS2
2
Show member pathways
12.64 AKT2 COL1A1 MAPK1 PTGS2
3 12.55 AKT2 BIRC5 MAPK1 PTGS2
4
Show member pathways
12.37 AKT2 COL1A1 MAPK1
5
Show member pathways
12.25 AKT2 BIRC5 MAPK1 PTGS2
6
Show member pathways
12.2 AKT2 BIRC5 MAPK1
7
Show member pathways
12.18 AKT2 MAPK1 PTGS2
8
Show member pathways
12.12 AKT2 MAPK1 PTGS2
9 12.07 AKT2 BIRC5 MAPK1 PTGS2
10
Show member pathways
12.04 AKT2 MAPK1 PTGS2
11
Show member pathways
12.02 AKT2 MAPK1 PHB
12
Show member pathways
11.98 AKT2 COL1A1 MAPK1
13
Show member pathways
11.95 AKT2 MAPK1 PTGS1 PTGS2
14 11.94 BIRC5 MAPK1 PTGS2
15 11.72 MAPK1 PTGS1 PTGS2
16 11.69 AKT2 MAPK1 PTGS2
17 11.63 AKT2 COL1A1 MAPK1
18 11.44 AKT2 BIRC5 MAPK1
20 11.37 BIRC5 PTGS2
21 11.37 COL1A1 PTGS1
22 11.34 MAPK1 PTGS2
23
Show member pathways
11.3 BIRC5 MAPK1 PTGS2
24 11.29 BIRC5 MAPK1
25 11.21 BIRC5 PTGS2
26 11.11 PTGS1 PTGS2
27 11.08 PTGS1 PTGS2
28 11.06 AKT2 PTGS1 PTGS2
29
Show member pathways
11.05 PTGS1 PTGS2
30 11.03 AKT2 MAPK1
31 11.01 AKT2 COL1A1 MAPK1 PTGS1
32 10.98 PTGS1 PTGS2
33 10.95 PTGS1 PTGS2
34 10.94 COL1A1 MAPK1
35 10.82 PTGS1 PTGS2
36 10.73 AKT2 BIRC5 MAPK1
37 10.69 PTGS1 PTGS2

GO Terms for Ovarian Epithelial Cancer

Cellular components related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 8.8 AKT2 MAPK1 PHB

Biological processes related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.5 AKT2 COL1A1 MAPK1
2 positive regulation of cell proliferation GO:0008284 9.46 AKT2 BIRC5 MAPK1 PTGS2
3 positive regulation of cell death GO:0010942 9.37 PHB PTGS2
4 prostaglandin metabolic process GO:0006693 9.26 PTGS1 PTGS2
5 prostaglandin biosynthetic process GO:0001516 8.96 PTGS1 PTGS2
6 cyclooxygenase pathway GO:0019371 8.62 PTGS1 PTGS2

Molecular functions related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxidase activity GO:0004601 8.96 PTGS1 PTGS2
2 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....